BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

immatics biotechnologies GmbH Receives 3 Research Grants Totaling 1.4 mn € to Advance its Early-Stage Cancer Immunotherapy Programs


7/7/2008 1:10:40 PM

Tuebingen, July 7, 2008 – immatics biotechnologies GmbH today announced that the company has received grants from three renowned public research funding programs to advance its early-stage cancer immunotherapy programs, with a special focus on glioblastoma and cancer stem cells. The government-sponsored so-called non-repayable funds add up to more than 1.4 million €.

The first grant covering approximately 540,000 € was awarded by the BioChancePLUS program of the German Federal Ministry of Education and Research (BMBF) and will support a collaboration of immatics with Dr Christel Herold-Mende of Heidelberg’s University Clinic and Dr Philipp Beckhove of the German Cancer Research Center (DKFZ) to develop a novel immunotherapeutic vaccine against glioblastoma (brain cancer), a condition with only very limited therapeutic options to date.

The second grant of approximately 250,000 € was awarded by the German federal state Baden-Wuerttemberg within a program supporting research activities of regional biotechnology companies. The funds will be dedicated to the preclinical evaluation of new immunomodulators and to the development of immunogenic formulations in combination with tumor-associated peptides. Such immunomodulators and formulations shall support the enhancement of the efficacy of current and future vaccine candidates.

The third and largest grant immatics has received will be used for the development of a novel class of therapeutic vaccines which trigger immune responses by specifically targeting cancer stem cells. Thereby they allow for a more effective and sustainable elimination of the tumor. Such vaccines may also be able to eliminate a variety of tumor entities and therefore have a significant market potential. The grant of approximately 625,000 € was awarded by the program “KMU-innovativ” of the German Federal Ministry of Education and Research (BMBF). Academic collaboration partners for this project will be Prof Dr Pierre-Yves Dietrich of the Hôpitaux Universitaires de Genève and Prof Dr Hans-Georg Rammensee of the Eberhard-Karls-Universitaet in Tuebingen.

“We are delighted about being awarded three important grants within the past months,” said Dr Harpreet Singh, Chief Scientific Officer of immatics. “The funds will allow us to strengthen our academic partnerships and to expand our research and preclinical development activities in major cancer fields such as glioblastoma and cancer stem cells. Consequently, our goal is to generate new findings in collaboration with our academic partners and use them to advance our programs in cancer immunotherapy.”

About immatics

immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. The lead product – IMA901 for therapy of renal cell cancer – is currently investigated in an international phase II clinical study. Since its foundation in 2000, immatics has raised more than €54 million (US$ 73 million) in private equity in two financing rounds. The company has a headcount of more than 60 people and is based in Tuebingen and Munich, Germany.

For additional information please visit www.immatics.com or contact:

Dr. Harpreet Singh
immatics biotechnologies GmbH
Phone: +49-7071-565125-10
E-mail: media@immatics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES